New hope for tough cancers: experimental drug targets Hard-to-Treat tumors
NCT ID NCT05119907
Summary
This study is testing whether the drug sacituzumab govitecan can help control advanced solid tumors that have grown despite standard chemotherapy. It is enrolling 53 adults with specific types of cancer, including some stomach, esophageal, cervical, lung, and bile duct cancers, that have progressed after other treatments. The main goal is to see if the drug shrinks tumors and for how long.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
Hefei, 230001, China
-
Beijing Cancer Hospital
Beijing, 100142, China
-
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, 100006, China
-
Chinese Academy of Medical Sciences Cancer Hospital
Beijing, 100021, China
-
Fujian Cancer Hospital
Fuzhou, 350014, China
-
Harbin Medical University Cancer Hospital
Harbin, 150076, China
-
Henan Cancer Hospital
Zhengzhou, 450000, China
-
Jiangsu Province Hospital
Nanjing, 210029, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, 310003, China
-
The First Hospital of Jilin University
Changchun, 130021, China
-
The Sixth Affiliated Hospital, Sun Yat-Sen University
Guangzhou, 510655, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 43006, China
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China
Conditions
Explore the condition pages connected to this study.